Anavex Life Sciences Corp (AVXL)

[lt2211]

This is year end selling accelerated, perhaps, by the company's "do nothing attitude" over the last 18 months. They are not acting like a company with a potential block buster product. That having been said, small biotech companies tend to do well in the first 90 days of each year as long as there isn't any specific bad news. AVXL will likely rise starting early next year.